Will Shrank, Bio + Health Venture Partner

In our quest to back exceptional founders effecting transformative change in our healthcare system, we recognize and embrace the need for partnership with “the system.” To do that well requires a deep understanding of the industry’s esoteric nuance and unintuitive laws of physics, plus practical experience executing within it. It also requires working with entities that can bring distribution and scale to novel care delivery, financing, and infrastructure solutions. As a manifestation of this philosophy, we welcome Dr. Will Shrank as a Venture Partner to the a16z Bio + Health fund.

Will’s areas of expertise coincide with multiple mega trends driving the evolution of our healthcare system—value-based care, Medicare and Medicaid, pharmacy benefits, medication adherence and affordability, and healthcare policy. He’s led teams across the industry, including at CMMI where he served as the Director of Evaluation, helping to design early value-based payment models, and CVS Health where he designed partnerships between retail, pharmacy, clinics and risk-bearing health systems. He was also the CMO of UPMC Health Plan, and most recently, led clinical operations, primary care, and government affairs as the CMO and Chief Corporate Affairs Officer of Humana. Alongside this experience at major institutions, he’s been an academic researcher, practicing physician, and an advisor to startups.

Will is one of the few in healthcare who have successfully bridged the interface between large corporations, government, and upstarts. Having known Will for over a decade, I know, like anyone who has worked with him, that he brings incredible energy, thoughtfulness, and pragmatic optimism to the playing field.

We are thrilled to have Will join the a16z Bio + Health team in support of our research team, portfolio companies, and ecosystem partners.


The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

Biology is eating the world

Sign up for our bio newsletter to get the a16z take on the future of biology and engineering.